fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      55   |   56   |   57   |   58   |   59   |   60   |   61   |   62   |   63   |   64   |   65      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2006-04-10 Eden Biodesign (GB)/Onyvax (GB)
 
therapeutic vaccine / ovarian cancer manufacturing
See details
2006-04-05 Innate Pharma (France)
Novo Nordisk (Denmark)
drugs targeting natural killer (NK) cells / cancer, infectious disease and auto-immune diseases other
See details
2006-04-03 Vaxon Biotech (France) Institut Pasteur (France)
 
cancer vaccines and animal models / cancer other
See details
2006-03-27 SGX Pharmaceuticals (USA)
Novartis (Switzerland)
novel treatments for Glivec® (imatinib)-resistant forms of chronic myeloid leukaemia (CML) /   R&D
commercialization/ distribution
See details
2006-03-22 IDM Pharma (USA)
Medison Pharma (Israel)
Mepact® /Junovan® / osteosarcoma commercialization/ distribution
See details
2006-03-21 Nicox (France)
Merck & Co (USA)
antihypertensive drugs based on Nicox's nitric oxide release technology / hypertension R&D
See details
2006-03-16 Daiichi Sankyo (Japan)
Morphosys (Germany)
therapeutic antibodies /   R&D
See details
2006-03-06 Myogen (USA)
GSK (UK)
ambrisentan (a selective endothelin receptor antagonist) / pulmonary arterial hypertension (PAH) commercialization/ distribution
See details
2006-03-02 Nicox (France)
Pfizer (USA)
  /   other
See details
2006-03-01 Morphosys (Germany)
Roche (Switzerland)
therapeutic antibodies / cancer R&D
See details
2006-02-27 BioSystems International (France)
AstraZeneca (UK)
biomarker discovery / arthrosis R&D
See details
2006-02-24 IDM Pharma (France-USA)
Genesis (Greece)
Mepact® /Junovan® ((mifamurtide-a synthetic derivative of muramyl pentapeptide) / osteosarcoma licensing
commercialization/ distribution
See details
2006-02-20 Alnylam (USA)
Novartis (Switzerland)
pandemic influenza treatments based on RNA interference / pandemic influenza R&D
See details
2006-02-13 Opsona Therapeutics (Ireland)
Wyeth (USA)
compounds based on Toll-like receptor (TLR) targets
/ inflammatory diseases
R&D
commercialization/ distribution
development
See details
2006-02-13 Biovitrum (Sweden)
Amgen (USA)
inhibitors of 11ß-HDS1 (11ß-hydroxysteroid dehydrogenase) / type 2 diabetes and metabolic diseases licensing
See details
[<<]      «      55   |   56   |   57   |   58   |   59   |   60   |   61   |   62   |   63   |   64   |   65      »      [65]